Gabelli Funds LLC decreased its position in shares of Zoetis (NYSE:ZTS) by 8.1% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 615,802 shares of the company’s stock after selling 54,500 shares during the quarter. Gabelli Funds LLC owned approximately 0.13% of Zoetis worth $51,426,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of the business. BlackRock Inc. lifted its holdings in Zoetis by 6.7% during the 1st quarter. BlackRock Inc. now owns 41,069,741 shares of the company’s stock worth $3,429,736,000 after buying an additional 2,584,199 shares in the last quarter. Clearbridge Investments LLC lifted its holdings in Zoetis by 3.9% during the 4th quarter. Clearbridge Investments LLC now owns 9,512,060 shares of the company’s stock worth $685,249,000 after buying an additional 353,622 shares in the last quarter. Brown Advisory Inc. lifted its holdings in Zoetis by 2.1% during the 4th quarter. Brown Advisory Inc. now owns 7,207,114 shares of the company’s stock worth $519,200,000 after buying an additional 149,095 shares in the last quarter. Northern Trust Corp lifted its holdings in Zoetis by 1.4% during the 1st quarter. Northern Trust Corp now owns 5,948,527 shares of the company’s stock worth $496,762,000 after buying an additional 82,183 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in Zoetis by 10.0% during the 1st quarter. Wells Fargo & Company MN now owns 5,845,480 shares of the company’s stock worth $488,156,000 after buying an additional 531,837 shares in the last quarter. 91.15% of the stock is currently owned by hedge funds and other institutional investors.
A number of research analysts have recently weighed in on the company. Piper Jaffray Companies set a $88.00 price target on Zoetis and gave the company a “buy” rating in a research note on Friday, February 16th. BMO Capital Markets set a $78.00 price target on Zoetis and gave the company a “hold” rating in a research note on Thursday, February 15th. Cantor Fitzgerald set a $90.00 price target on Zoetis and gave the company a “buy” rating in a research note on Thursday, February 15th. Stifel Nicolaus reissued a “buy” rating and issued a $86.00 price target (up previously from $84.00) on shares of Zoetis in a research note on Friday, February 16th. Finally, Morgan Stanley downgraded Zoetis from an “overweight” rating to an “equal weight” rating and set a $70.00 price target on the stock. in a research note on Monday, March 19th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. Zoetis currently has a consensus rating of “Buy” and an average target price of $82.67.
ZTS opened at $84.38 on Wednesday. The company has a debt-to-equity ratio of 2.51, a current ratio of 4.27 and a quick ratio of 2.83. Zoetis has a 12 month low of $59.50 and a 12 month high of $86.38. The firm has a market capitalization of $41.31 billion, a P/E ratio of 35.16, a PEG ratio of 1.88 and a beta of 0.97.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Wednesday, May 2nd. The company reported $0.75 EPS for the quarter, beating the Zacks’ consensus estimate of $0.69 by $0.06. Zoetis had a net margin of 17.97% and a return on equity of 68.51%. The business had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.35 billion. During the same quarter in the prior year, the company earned $0.53 EPS. The firm’s quarterly revenue was up 11.0% on a year-over-year basis. sell-side analysts forecast that Zoetis will post 3.06 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 4th. Shareholders of record on Friday, July 20th will be issued a dividend of $0.126 per share. This represents a $0.50 dividend on an annualized basis and a yield of 0.60%. The ex-dividend date of this dividend is Thursday, July 19th. Zoetis’s dividend payout ratio (DPR) is presently 20.83%.
In other Zoetis news, insider Kristin C. Peck sold 4,877 shares of the stock in a transaction dated Tuesday, May 1st. The stock was sold at an average price of $83.46, for a total transaction of $407,034.42. Following the completion of the transaction, the insider now owns 42,652 shares in the company, valued at approximately $3,559,735.92. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Heidi C. Chen sold 7,383 shares of the stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $84.71, for a total value of $625,413.93. Following the transaction, the insider now owns 20,162 shares of the company’s stock, valued at approximately $1,707,923.02. The disclosure for this sale can be found here. In the last quarter, insiders have sold 44,713 shares of company stock valued at $3,703,019. Corporate insiders own 0.35% of the company’s stock.
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.